Evidence map›Paper›PMID 29028415›Full record

ReviewRNA biology2018

CRISPR/Cas9-mediated noncoding RNA editing in human cancers.

Jie Yang, Xiaodan Meng, Jinchang Pan, Nan Jiang, Chengwei Zhou, Zhenhua Wu, Zhaohui Gong

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in RNA biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 122 citations in OpenAlex.

  1. Dual-functional nanoplatform for simultaneous degradation of circRNAJournal of Zhejiang University. Science. B · 2026
    Article
  2. Review
  3. Review
  4. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Pulling the trigger: Noncoding RNAs in white adipose tissue browning.Reviews in endocrine & metabolic disorders · 2024
    Review
  15. Review
  16. Emerging roles of long non-coding RNAs in osteosarcoma.Frontiers in molecular biosciences · 2024
    Review
  17. Review
  18. Review
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jie Yanga Department of Biochemistry and Molecular Biology , Medical School of Ningbo University , Ningbo , Zhejiang , China.
Xiaodan Menga Department of Biochemistry and Molecular Biology , Medical School of Ningbo University , Ningbo , Zhejiang , China.
Jinchang Pana Department of Biochemistry and Molecular Biology , Medical School of Ningbo University , Ningbo , Zhejiang , China.
Nan Jianga Department of Biochemistry and Molecular Biology , Medical School of Ningbo University , Ningbo , Zhejiang , China.ORCID 0000-0002-8423-7675
Chengwei Zhouc Department of Thoracic Surgery , The Affiliated Hospital of Medical School of Ningbo University , Ningbo , Zhejiang , China.
Zhenhua Wud Department of Otolaryngology Head and Neck Surgery , The Affiliated Ningbo Medical Center Lihuili Eastern Hospital of Medical School of Ningbo University , Ningbo , Zhejiang , China.
Zhaohui Gonga Department of Biochemistry and Molecular Biology , Medical School of Ningbo University , Ningbo , Zhejiang , China.
Ningbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is characterized by multiple genetic and epigenetic alterations, including a higher prevalence of mutations of oncogenes and/or tumor suppressors. Mounting evidences have shown that noncoding RNAs (ncRNAs) are involved in the epigenetic regulation of cancer genes and their associated pathways. The clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease 9 (CRISPR/Cas9) system, a revolutionary genome-editing technology, has shed light on ncRNA-based cancer therapy. Here, we briefly introduce the classifications and mechanisms of CRISPR/Cas9 system. Importantly, we mainly focused on the applications of CRISPR/Cas9 system as a molecular tool for ncRNA (microRNA, long noncoding RNA and circular RNA, etc.) editing in human cancers, and the novel techniques that are based on CRISPR/Cas9 system. Additionally, the off-target effects and the corresponding solutions as well as the challenges toward CRISPR/Cas9 were also evaluated and discussed. Long- and short-ncRNAs have been employed as targets in precision oncology, and CRISPR/Cas9-mediated ncRNA editing may provide an excellent way to cure cancer.

Indexed as

CRISPR-Cas SystemsEndonucleasesGenetic TherapyHumansMicroRNAsNeoplasmsRNARNA, CircularRNA EditingRNA, UntranslatedEndonucleasesMicroRNAsRNARNA, CircularRNA, Untranslatedcancercircular RNACRISPR-Cas9genome editinglong noncoding RNAmicroRNARNA editing

Identifiers

PMID29028415
PMCPMC5785983
OpenAlexW2763417058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.